|
55 Companies |
|
51 Products |
|
51 Products |
|
62 Mechanisms of Action |
|
0 Trials |
|
1119 News |
|
| «12...891011121314151617181920» |
- Enrollment change: Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients (clinicaltrials.gov) - Dec 20, 2012
P=N/A, N=1200, Recruiting, Sponsor: Shanghai 10th People's Hospital
N=800 --> 1200
- Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Trial initiation date: Understanding the Immune Response to Two Different Meningitis Vaccines (clinicaltrials.gov) - Dec 19, 2012
P4, N=15, Active, not recruiting, Sponsor: University of Oxford
N=800 --> 1200 Initiation date: Aug 2012 --> Dec 2012
- Enrollment open: Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=6000, Recruiting, Sponsor: Aga Khan University
Initiation date: Aug 2012 --> Dec 2012 Not yet recruiting --> Recruiting
- Trial termination: Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA (clinicaltrials.gov) - Dec 17, 2012
P=N/A, N=764, Terminated, Sponsor: MicroPhage, Inc.
Not yet recruiting --> Recruiting Recruiting --> Terminated; Results did not meet study requirements.
- Enrollment change: Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA (clinicaltrials.gov) - Dec 17, 2012
P=N/A, N=764, Terminated, Sponsor: MicroPhage, Inc.
Recruiting --> Terminated; Results did not meet study requirements. N=600 --> 764
- Enrollment open: Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients (clinicaltrials.gov) - Dec 15, 2012
P=N/A, N=1200, Recruiting, Sponsor: Shanghai 10th People's Hospital
N=600 --> 764 Not yet recruiting --> Recruiting
- Cubicin (daptomycin) / Merck (MSD)
Trial termination: Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs) (clinicaltrials.gov) - Dec 13, 2012
P4, N=11, Terminated, Sponsor: St. John Health System, Michigan
Not yet recruiting --> Recruiting Recruiting --> Terminated; Low patient enrollment
- Trial completion, Surgery: INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery (clinicaltrials.gov) - Dec 13, 2012
P4, N=525, Completed, Sponsor: Medical University of Gdansk
Recruiting --> Terminated; Low patient enrollment Active, not recruiting --> Completed
- Enrollment open: EIDECS: End-of-life Decision-making in Patients With Sepsis-related Organ Failure (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=180, Recruiting, Sponsor: Center for Sepsis Control and Care, Germany
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Trial completion: Value of the LightCycler (clinicaltrials.gov) - Dec 3, 2012
P4, N=150, Completed, Sponsor: University Hospital Muenster
Active, not recruiting --> Recruiting Recruiting --> Completed
- | paracetamol / Generic mfg.
New P2a trial: ACROSS: Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis (clinicaltrials.gov) - Nov 29, 2012
P2a, N=51, Completed, Sponsor: Vanderbilt University
- Cubicin (daptomycin) / Merck (MSD)
New P4 trial: STOP-NT: Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients (clinicaltrials.gov) - Nov 26, 2012
P4, N=100, Terminated, Sponsor: Henry Ford Health System
- ||||| meropenem / Generic mfg.
PK/PD data, Trial initiation date: Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis (clinicaltrials.gov) - Nov 20, 2012
P3, N=550, Recruiting, Sponsor: PENTA Foundation
Recruiting --> Completed Initiation date: Mar 2012 --> Sep 2012
- |||||| meropenem / Generic mfg.
Enrollment open, PK/PD data: Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis (clinicaltrials.gov) - Nov 20, 2012
P3, N=550, Recruiting, Sponsor: PENTA Foundation
Initiation date: Mar 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- fluconazole oral / Generic mfg.
Enrollment change: Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers (clinicaltrials.gov) - Nov 16, 2012
P1, N=13, Completed, Sponsor: Daniel Benjamin
Not yet recruiting --> Recruiting N=48 --> 13
- fluconazole oral / Generic mfg.
Trial completion: Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers (clinicaltrials.gov) - Nov 16, 2012
P1, N=13, Completed, Sponsor: Daniel Benjamin
N=48 --> 13 Enrolling by invitation --> Completed
- ||||| Cubicin (daptomycin) / Merck (MSD)
New P4 trial: Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) (clinicaltrials.gov) - Nov 15, 2012
P4, N=75, Recruiting, Sponsor: Cubist Pharmaceuticals
- Enrollment change: Clinical Evaluation of e- Ab Sensor - Based Real-time Diagnosis of Serum Procalcitonin Level (clinicaltrials.gov) - Nov 14, 2012
P=N/A, N=200, Completed, Sponsor: National Taiwan University Hospital
Enrolling by invitation --> Completed N=100 --> 200
- Enrollment change: Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation (clinicaltrials.gov) - Nov 14, 2012
P4, N=101, Completed, Sponsor: Hospital Sant Joan de Deu
N=100 --> 200 N=146 --> 101
- Trial completion: Clinical Evaluation of e- Ab Sensor - Based Real-time Diagnosis of Serum Procalcitonin Level (clinicaltrials.gov) - Nov 14, 2012
P=N/A, N=200, Completed, Sponsor: National Taiwan University Hospital
N=146 --> 101 Recruiting --> Completed
- Trial completion: Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation (clinicaltrials.gov) - Nov 14, 2012
P4, N=101, Completed, Sponsor: Hospital Sant Joan de Deu
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: Phase I STEBVax in Healthy Adults (clinicaltrials.gov) - Nov 14, 2012
P1, N=29, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Recruiting
- Timcynis (ticarcillin and clavulanic acid) / Emcure
Trial withdrawal: Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants (clinicaltrials.gov) - Nov 11, 2012
P1, N=0, Withdrawn, Sponsor: Phillip Brian Smith
Active, not recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Timcynis (ticarcillin and clavulanic acid) / Emcure
Enrollment change: Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants (clinicaltrials.gov) - Nov 11, 2012
P1, N=0, Withdrawn, Sponsor: Phillip Brian Smith
Not yet recruiting --> Withdrawn N=16 --> 0
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Enrollment open, IO biomarker: The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis (clinicaltrials.gov) - Nov 11, 2012
P3, N=20, Recruiting, Sponsor: Radboud University
N=16 --> 0 Not yet recruiting --> Recruiting
- New P1 trial: DAMSEL1: Melatonin in Healthy Volunteers (clinicaltrials.gov) - Nov 7, 2012
P1, N=20, Completed, Sponsor: University of Aberdeen
- || New P2/3 trial: Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing <1500 g at Birth (clinicaltrials.gov) - Nov 6, 2012
P2/3, N=1282, Not yet recruiting, Sponsor: All India Institute of Medical Sciences, New Delhi
- Trial completion: SEPSISPAM: Assessment of Two Levels of Arterial Pressure on Survival in Patients With Septic Shock (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=800, Completed, Sponsor: University Hospital, Angers
Not yet recruiting --> Recruiting Recruiting --> Completed
- || New P3 trial: VANCS II: Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients (clinicaltrials.gov) - Oct 29, 2012
P3, N=250, Recruiting, Sponsor: Instituto do Cancer do Estado de S
- | Enrollment open: VANCS II: Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients (clinicaltrials.gov) - Oct 28, 2012
P3, N=250, Recruiting, Sponsor: Instituto do Cancer do Estado de S
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination: LAVISS_01: Alterations of Immunologic Mediators During Severe Sepsis (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=20, Terminated, Sponsor: Klinikum St. Georg gGmbH
Not yet recruiting --> Recruiting Recruiting --> Terminated; anticipated number of patients could not be reached
- Enrollment change: LAVISS_01: Alterations of Immunologic Mediators During Severe Sepsis (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=20, Terminated, Sponsor: Klinikum St. Georg gGmbH
Recruiting --> Terminated; anticipated number of patients could not be reached N=48 --> 20
- Enrollment change: The CRISIS Prevention Study (clinicaltrials.gov) - Oct 17, 2012
P3, N=293, Terminated, Sponsor: Michael Dean
N=48 --> 20 N=600 --> 293
- Enrollment open: Immune Activation, Hypoxia and Vasoreaction in Sepsis of Pulmonary Versus Abdominal Origin (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=20, Recruiting, Sponsor: University Hospital Mannheim
N=600 --> 293 Not yet recruiting --> Recruiting
- Enrollment open: Improving Maternal and Child Health in India: Evaluating Demand and Supply Side Strategies (IMATCHINE) (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=14990, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment change: Ascorbic Acid (Vitamin C) Infusion in Human Sepsis (clinicaltrials.gov) - Oct 10, 2012
P1/2, N=24, Completed, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting N=30 --> 24
- New P3 trial: Administration of Protein C Concentrates in Adult Critically Ill Septic Patients (clinicaltrials.gov) - Oct 10, 2012
P3, N=0, Recruiting, Sponsor: Università Vita-Salute San Raffaele
- Trial completion: Ascorbic Acid (Vitamin C) Infusion in Human Sepsis (clinicaltrials.gov) - Oct 10, 2012
P1/2, N=24, Completed, Sponsor: Virginia Commonwealth University
N=30 --> 24 Recruiting --> Completed
- | Cubicin (daptomycin) / Merck (MSD)
Trial termination: RENSE: Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (clinicaltrials.gov) - Oct 8, 2012
P4, N=92, Terminated, Sponsor: Cubist Pharmaceuticals
Recruiting --> Completed Recruiting --> Terminated; Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop.
- Cubicin (daptomycin) / Merck (MSD)
Enrollment change: RENSE: Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (clinicaltrials.gov) - Oct 8, 2012
P4, N=92, Terminated, Sponsor: Cubist Pharmaceuticals
Recruiting --> Terminated; Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop. N=120 --> 92
- levofloxacin / Generic mfg.
Trial completion: BK Treatment Study (clinicaltrials.gov) - Oct 8, 2012
P4, N=46, Completed, Sponsor: Brigham and Women's Hospital
N=120 --> 92 Recruiting --> Completed
- ||||| ceftaroline fosamil / Generic mfg.
New P4 trial: Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - Oct 3, 2012
P4, N=60, Active, not recruiting, Sponsor: Cerexa, Inc.
- Enrollment closed, Adverse events: Predicting Complications in Women With Toxaemia (clinicaltrials.gov) - Oct 3, 2012
P=N/A, N=2000, Active, not recruiting, Sponsor: University of British Columbia
Recruiting --> Completed Recruiting --> Active, not recruiting
- Clinical data, Enrollment change: DHA-IRCO: Effect of Docosahexaenoic Acid on the Inflammatory Response and Clinical Outcomes From Surgical Patients (clinicaltrials.gov) - Sep 30, 2012
P2, N=55, Completed, Sponsor: Coordinación de Investigación en Salud, Mexico
Recruiting --> Active, not recruiting N=36 --> 55
- Clinical data, Trial completion: DHA-IRCO: Effect of Docosahexaenoic Acid on the Inflammatory Response and Clinical Outcomes From Surgical Patients (clinicaltrials.gov) - Sep 30, 2012
P2, N=55, Completed, Sponsor: Coordinación de Investigación en Salud, Mexico
N=36 --> 55 Enrolling by invitation --> Completed
- Clinical: Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=66, Completed, Sponsor: Erasme University Hospital
- Enrollment open: Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=76, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- Enrollment change: ERNIE3: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E. (clinicaltrials.gov) - Sep 12, 2012
P=N/A, N=1500, Completed, Sponsor: Katholieke Universiteit Leuven
Not yet recruiting --> Recruiting N=4000 --> 1500
- Trial completion: ERNIE3: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E. (clinicaltrials.gov) - Sep 12, 2012
P=N/A, N=1500, Completed, Sponsor: Katholieke Universiteit Leuven
N=4000 --> 1500 Recruiting --> Completed
- | tranexamic acid oral / Generic mfg.
New P2 trial: Single Dose Enteral Tranexamic Acid in Critically Ill Patients (clinicaltrials.gov) - Sep 10, 2012
P2, N=200, Recruiting, Sponsor: San Diego Veterans Healthcare System